Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • Non-Hodgkin Lymphoma • CAR-T • Hematology • DLBCL
How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?
Can grade 1 toxicities (e.g. CRS) be monitored safely as an outpatient?
Answer from: Medical Oncologist at Academic Institution
Multiple bispecific antibodies (BsAbs) targeting CD20 on lymphoma cells and CD3 on T-cells are now available in follicular and large B-cell lymphoma. A multi-disciplinary team with knowledge of the different BsAb indications and possible toxicities is an important aspect of safely administering thes...
Sign In or Register to read more